Beijing New Weipao Pharmaceutical Technology

Beijing New Weipao Pharmaceutical Technology is a Chinese biotechnology company focused on the development of innovative small molecule therapeutics for metabolic diseases. The company specializes in the discovery of multi-target agonists, particularly those targeting the GLP-1, GIP, and glucagon receptors, to treat conditions such as type 2 diabetes and obesity. By leveraging its expertise in medicinal chemistry, New Weipao aims to create oral alternatives to existing injectable peptide therapies. The company is currently advancing several candidates through the pre-clinical stage to address the growing global burden of metabolic disorders.